[{"text": "LIVE The latest news and updates on Trump's tariffs Axsome Shares Rise 19% in a Month: What's Driving the Rally? Zacks Equity Research Fri, Jan 24, 2025, 6:32 PM 4 min read Axsome Therapeutics \u2019 AXSM shares have rallied 19.4% in the past month against the industry\u2019s decrease of 0.2%, driven by investor enthusiasm about the company\u2019s encouraging preliminary sales numbers for the fourth quarter and full year 2024. Axsome\u2019s commercial portfolio includes Auvelity (AXS-05) which was launched in the United States in 2022 to treat major depressive disorder. It was the company\u2019s first approved drug. The company is conducting several label expansion studies on Auvelity targeting other central nervous system (CNS) disorders like Alzheimer\u2019s disease (AD) associated agitation and smoking cessation. Approval for expanded indications can potentially boost the drug\u2019s sales in future quarters. Axsome acquired U.S. rights to Sunosi (solriamfetol), a commercialized drug targeting narcolepsy, from Jazz Pharmaceuticals JAZZ in May 2022. It began selling Sunosi in the U.S. market in May 2022 and certain international markets in November 2022. Jazz received approval for Sunosi as a treatment for narcolepsy in 2019. AXSM's Q4 & 2024 Preliminary Results Earlier this month, Axsome reported robust preliminary net product revenues for Auvelity and Sunosi for the fourth quarter and full year 2024. Auvelity sales in the fourth quarter of 2024 are expected to be around $92.6 million, bringing the full-year number to around $291.4 million. Sunosi net product revenues are expected to be around $25.7 million and $93.8 million for the fourth quarter and full year 2024, respectively. The strong preliminary sales for Auvelity and Sunosi can be attributed as the reasons for the stock\u2019s upside in the past month. Zacks Investment Research Image Source: Zacks Investment Research Auvelity has been witnessing strong sales uptake since its launch. Also, the acquisition of Sunosi from Jazz diversified Axsome\u2019s portfolio, helping it reach a larger patient population and driving the company\u2019s growth prospects. Currently, two separate phase III studies are evaluating Auvelity for treating agitation associated with AD. In December 2024, the company announced top-line data from the ACCORD-2 and ADVANCE-2 studies, which evaluated Auvelity for treating agitation associated with AD. The ACCORD-2 study met the primary endpoint wherein treatment with AXS-05 statistically and significantly delayed the time to relapse of agitation, as assessed by the Cohen-Mansfield Agitation Inventory (CMAI) total score versus placebo in the given patient population. However, the ADVANCE-2 study did not demonstrate statistical significance for the primary endpoint, which was the change in the CMAI total score from baseline to week five. Treatment with AXS-05 was safe and well tolerated in both controlled studies. Story Continues Based on these efficacy and safety results, Axsome plans to submit a new drug application for AXS-05 in AD agitation to the FDA in the second half of 2025. Per some reports, despite the mixed results from the above studies, AXSM remains hopeful for potential approval for Auvelity in AD agitation. This could be an important catalyst for the stock going forward. AXSM's Other Pipeline Candidates Hold Promise Axsome\u2019s portfolio of pipeline candidates includes AXS-07, AXS-12 and AXS-14, all of which are being developed for various CNS indications. AXS-07 is being developed for the acute treatment of migraine. The FDA accepted AXSM\u2019s\u00a0resubmitted new drug application, seeking approval for AXS-07 for the acute treatment of migraine in September 2024. A final decision from the regulatory body is expected on Jan. 31, 2025. AXS-14 (esreboxetine) is being developed for the treatment of fibromyalgia. AXS-12 (reboxetine) is being evaluated in late-stage studies for the treatment of narcolepsy. Successful development and potential approval for any of these candidates are likely to drive Axsome\u2019s growth prospects and should continue the upward momentum for the stock in 2025. Axsome Therapeutics, Inc. Price Axsome Therapeutics, Inc. Price Axsome Therapeutics, Inc. price | Axsome Therapeutics, Inc. Quote AXSM's Zacks Rank & Stocks to Consider Axsome currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Voyager Therapeutics\u2019 loss per share have narrowed from $1.72 to $1.58 for 2025. In the past year, shares of VYGR have plunged 27.3%. VYGR\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%. In the past 60 days, estimates for Castle Biosciences\u2019 loss per share have narrowed from $1.88 to $1.70 for 2025. In the past year, shares of CSTL have surged 28.4%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXSM", "date": "2025-01-24T18:32:00", "sentiment": {"score": 0.9324584528803825, "confidence": 0.9456952214241028, "probabilities": {"positive": 0.9456952214241028, "negative": 0.013236768543720245, "neutral": 0.04106803983449936}}, "embedding": [-0.06150056794285774, -0.103215292096138, -0.1258416324853897, -0.048506952822208405, -0.029212774708867073, 0.03325849398970604, 0.06611672043800354, 0.1930152028799057, 0.032541219145059586, 0.04689754545688629, -0.07951241731643677, 0.17995619773864746, 0.05056912079453468, 0.05150280147790909, 0.051882870495319366, 0.0634538009762764, 0.09815013408660889, 0.023436881601810455, -0.14780586957931519, 0.10003404319286346, -0.011473879218101501, -0.045022718608379364, 0.05768071860074997, -0.024425562471151352, -0.009314777329564095, 0.10650382936000824, -0.11007773876190186, -0.1568966805934906, -0.07829947024583817, -0.09283722937107086, 0.020094048231840134, 0.20255474746227264, -0.0027938978746533394, -0.047690048813819885, -0.032160114496946335, -0.06354460120201111, -0.10835521668195724, 0.0952618271112442, -0.017887698486447334, -0.05737622082233429, 0.023191992193460464, -0.10672265291213989, -0.14900514483451843, 0.004041147418320179, -0.08522511273622513, -0.14963304996490479, -0.05966031551361084, 0.020298974588513374, 0.11617828905582428, 0.11542698740959167, -0.08972608298063278, -0.1373307704925537, 0.03602072224020958, 0.06704708188772202, -0.07985997945070267, 0.08492113649845123, -0.15115970373153687, 0.03681514412164688, -0.027225840836763382, 0.05687347799539566, 0.027765151113271713, -0.059532079845666885, -0.04652222990989685, 0.009672202169895172, 0.11099626123905182, 0.006928105838596821, -0.04985971748828888, -0.09554220736026764, -0.057957425713539124, -0.01192996371537447, 0.10432251542806625, -0.1085832342505455, 0.005744284950196743, -0.005257361568510532, -0.006046449765563011, 0.14837801456451416, 0.18147492408752441, 0.041715413331985474, 0.1499696671962738, -0.14608465135097504, 0.11521212011575699, 0.1219019889831543, 0.06907298415899277, -0.01710519939661026, 0.08501989394426346, 0.09308204054832458, 0.013545386493206024, 0.11229047179222107, 0.021373484283685684, 0.022867027670145035, 0.0734221339225769, 0.04466162994503975, -0.1022675409913063, -0.09839068353176117, -0.056918270885944366, -0.04367321357131004, -0.032321102917194366, 0.031038010492920876, -0.03441693261265755, 0.13830533623695374, 0.09716615825891495, 0.06078699976205826, 0.007016012445092201, -0.12042170763015747, -0.04018765687942505, -0.09107853472232819, 0.11126784980297089, -0.10287325084209442, -0.011206274852156639, 0.1425367295742035, -0.13874438405036926, 0.026110652834177017, -0.04299086332321167, -0.04112529754638672, -0.03598886728286743, 0.1279200315475464, -0.0962488204240799, 0.04744989424943924, 0.24820081889629364, -0.0955267921090126, 0.0649639219045639, 0.057447630912065506, 0.04249589145183563, 0.002047737129032612, 0.07895456999540329, 0.028104664757847786, -0.15769533812999725, 1.1106533477469609e-32, -0.1013665571808815, 0.13511955738067627, -0.03963719680905342, -0.05082011595368385, -0.01391792856156826, 0.010624104179441929, 0.06810341775417328, 0.10094353556632996, -0.05572884529829025, -0.07947933673858643, -0.2199895679950714, 0.13028286397457123, 0.05259305611252785, 0.10124004632234573, 0.032578855752944946, -0.07977122068405151, 0.033271513879299164, -0.0665348544716835, 0.05090232193470001, -0.1374547928571701, 0.008185130544006824, 0.06273319572210312, -0.09735797345638275, 0.1254451423883438, -0.16530907154083252, -0.01925918459892273, -0.1256166696548462, 0.08321096748113632, 0.049063846468925476, 0.0736156702041626, -0.05085757374763489, 0.07280117273330688, -0.0436076857149601, -0.06402816623449326, -0.052624523639678955, 0.08827448636293411, -0.06249331682920456, -0.11686798930168152, 0.06955116987228394, -0.03908166289329529, -0.06765884906053543, 0.23445063829421997, -0.11486031860113144, -0.028204921633005142, -0.05380083620548248, 0.0027907928451895714, -0.10331815481185913, -0.03807569295167923, 0.07089833170175552, -0.056737251579761505, -0.020023692399263382, 0.037407420575618744, -0.011639142408967018, -0.09521466493606567, -0.09016817063093185, 0.03412741422653198, -0.12646669149398804, -0.09276828169822693, 0.027308207005262375, 0.11691596359014511, 0.07318435609340668, 0.01765882596373558, 0.026927722617983818, 0.026853349059820175, -0.13483145833015442, 0.18701887130737305, 0.0551113523542881, -0.0900246649980545, -0.02993949130177498, -0.03843826800584793, -0.019830795004963875, -0.011114401742815971, 0.12445152550935745, -0.02624688297510147, 0.1287083923816681, -0.06737876683473587, 0.12054333090782166, 0.013728308491408825, 0.03733857721090317, -0.023153968155384064, -0.005385720171034336, -0.10045123100280762, -0.013720134273171425, 0.1379908323287964, -0.013057298958301544, -0.013131698593497276, 0.02634430304169655, 0.02981550619006157, -0.13184213638305664, -0.028995506465435028, 0.046095531433820724, 0.005208803340792656, -0.03279475122690201, 0.1275443285703659, -0.020895304158329964, -1.0899420189062353e-32, -0.07391460239887238, 0.04671606421470642, -0.02069525606930256, -0.04747539386153221, 0.024204138666391373, 0.026936382055282593, 0.024209490045905113, -0.0923335999250412, -0.02317112684249878, -0.02272885851562023, 0.08043427765369415, 0.02077699452638626, 0.0711447149515152, 0.028818979859352112, -0.10560047626495361, 0.00897242408245802, -0.09600074589252472, -0.028725124895572662, 0.06266164034605026, 0.009877162054181099, -0.012202487327158451, 0.23640429973602295, -0.074967160820961, 0.13056516647338867, 0.02231147699058056, -0.007537211757153273, 0.03932023048400879, 0.02793549746274948, 0.03544589504599571, 0.0798286646604538, -0.07678036391735077, 0.04610053449869156, -0.2226298749446869, -0.04021324962377548, -0.0457998551428318, 0.05711193010210991, 0.006555795669555664, -0.16654393076896667, -0.16140231490135193, -0.0903620719909668, 0.08482491970062256, -0.032536014914512634, 0.01710822433233261, 0.05568277835845947, 0.14436939358711243, -0.05527186766266823, -0.003030693158507347, 0.03798241168260574, 0.08198051154613495, -0.01758093759417534, 0.007948117330670357, 0.057811371982097626, 0.029474683105945587, 0.0691412016749382, -0.09475066512823105, 0.05327783152461052, 0.06238875165581703, -0.03836992383003235, -0.12671348452568054, -0.004937583580613136, -0.027456700801849365, 0.12307877093553543, -0.06275047361850739, -0.11337707191705704, 0.12370458990335464, 0.0310432780534029, 0.0665581226348877, 0.059260908514261246, 0.0512930229306221, -0.10690805315971375, 0.07082338631153107, 0.00457919854670763, -0.013753153383731842, 0.00031411717645823956, -0.07634486258029938, 0.11609797924757004, 0.08820706605911255, -0.1725517362356186, -0.09779783338308334, -0.033185817301273346, -0.02255883440375328, 0.058777086436748505, 0.048733845353126526, 0.05766849219799042, -0.13671229779720306, 0.04185616225004196, 0.07254680246114731, -0.019757797941565514, -0.19725698232650757, 0.06852096319198608, -0.039665088057518005, -0.09897705912590027, -0.1465141326189041, 0.12074015289545059, 0.06554950028657913, -1.0056977828298841e-07, 0.11547903716564178, -0.02818833291530609, 0.08508837968111038, -0.016907949000597, 0.05234737694263458, 0.015446124598383904, -0.01207084208726883, 0.04306471720337868, -0.018308447673916817, 0.16226600110530853, -0.04943837225437164, 0.11779694259166718, -0.11053059995174408, 0.0018101846799254417, -0.1492922604084015, 0.10130742192268372, 0.006614205427467823, 0.11591655015945435, -0.0640653446316719, -0.054721079766750336, -0.06421232223510742, 0.06708656251430511, 0.13627144694328308, -0.13038118183612823, 0.06638076156377792, -0.10523529350757599, 0.023571111261844635, 0.03897203132510185, -0.009858353063464165, -0.00517963245511055, -0.07027657330036163, -0.010461428202688694, 0.1485307663679123, -0.10598251223564148, -0.021618030965328217, -0.16276782751083374, 0.020047664642333984, -0.018223050981760025, 0.04565761983394623, 0.016026729717850685, -0.08394188433885574, 0.040774572640657425, -0.0034579411149024963, 0.02712433785200119, 0.006711282767355442, -0.13208897411823273, -0.04457376152276993, -0.13380412757396698, 0.1115550845861435, -0.13704296946525574, 0.07429537177085876, 0.009545601904392242, 0.019350022077560425, -0.10613492131233215, -0.036951836198568344, 0.02999887242913246, -0.20496509969234467, 0.015689540654420853, -0.06496170163154602, -0.02726670168340206, 0.053589049726724625, -0.10625889897346497, 0.04672122746706009, 0.03315826505422592], "changes": {"1wk": 3.2489559250228304}}, {"text": "LIVE The latest news and updates on Trump's tariffs Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue Axsome Therapeutics, Inc. Mon, Jan 13, 2025, 3:00 PM 6 min read In This Article: AXSM Axsome Therapeutics, Inc. Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8 million, respectively NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary net product revenue for the fourth quarter and full year ended December 31, 2024. \u201cWe delivered strong revenue growth in 2024 and significantly advanced our industry leading neuroscience pipeline, including achievement of positive Phase 3 results for AXS-05 in Alzheimer\u2019s disease agitation and for AXS-12 in narcolepsy, supporting planned regulatory filings for these indications and products in 2025,\u201d said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. \u201cWe also look to carry our commercial momentum into 2025 with continued growth for Auvelity and Sunosi, and are making active launch preparations for AXS-07 for the acute treatment of migraine, if approved.\u201d Preliminary Fourth Quarter and Full Year 2024 Net Product Revenue (Unaudited) Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $118.3 million and $385.2 million for the fourth quarter and full year of 2024, respectively. Auvelity\u00ae net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and full year of 2024, respectively. Sunosi\u00ae net product revenue is expected to be approximately\u00a0$25.7 million and $93.8 million for the fourth quarter and full year of 2024, respectively. The foregoing information reflects the Company's estimate with respect to net product revenue for Auvelity and Sunosi based on currently available unaudited information. This announcement is not a comprehensive statement of Axsome\u2019s financial results and is subject to completion of Axsome\u2019s financial closing procedures. Axsome\u2019s final financial results will be issued upon completion of its closing procedures and may vary from these preliminary estimates. About Axsome Therapeutics, Inc. Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder and excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain\u2019s biggest problems so patients and their loved ones can flourish. Story Continues Forward Looking Statements Certain matters discussed in this press release are \u201cforward-looking statements\u201d. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company\u2019s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of the Company\u2019s Sunosi\u00ae and Auvelity\u00ae products and the success of the Company\u2019s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company\u2019s ability to maintain and expand payer coverage; the success, timing and cost of the Company\u2019s ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund the Company\u2019s disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (\u201cNDA\u201d) for any of the Company\u2019s current product candidates, including statements regarding the ability of the ACCORD and ADVANCE clinical trials to support the filing of an NDA for Alzheimer\u2019s disease agitation; the Company\u2019s ability to fund additional clinical trials to continue the advancement of the Company\u2019s product candidates; the timing of and the Company\u2019s ability to obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, the Company\u2019s product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company\u2019s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to the Company\u2019s special protocol assessment for the MOMENTUM clinical trial; the Company\u2019s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company\u2019s research and development programs and collaborations; the success of the Company\u2019s license agreements; the acceptance by the market of the Company\u2019s products and product candidates, if approved; the Company\u2019s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company\u2019s commercial launch of its other product candidates, if approved, and the potential impact on the Company\u2019s anticipated cash runway; differences between the Company\u2019s 2024 preliminary financial information disclosed herein as compared to the Company\u2019s final 2024 audited financial statements; the fact that estimated net product revenue is not a comprehensive statement of the Company\u2019s financial results and is subject to completion of Company\u2019s financial closing procedures; the Company\u2019s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company\u2019s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. Investors: Mark Jacobson Chief Operating Officer Tel: 212-332-3243 Email: mjacobson@axsome.com Media: Darren Opland Director, Corporate Communications Tel: 929-837-1065 Email: dopland@axsome.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXSM", "date": "2025-01-13T15:00:00", "sentiment": {"score": 0.3410355672240257, "confidence": 0.3545723259449005, "probabilities": {"positive": 0.3545723259449005, "negative": 0.013536758720874786, "neutral": 0.6318909525871277}}, "embedding": [-0.11328951269388199, -0.12267468124628067, -0.05817018449306488, -0.07613017410039902, -0.03911321610212326, -0.0369800329208374, 0.0732235312461853, 0.2277441769838333, 0.04200120270252228, 0.11872588843107224, -0.003893105313181877, 0.11944358050823212, 0.004605855792760849, 0.11469519138336182, 0.0011244677007198334, 0.07421977818012238, 0.03158049285411835, -0.05830638110637665, -0.06503412127494812, 0.11916959285736084, 0.11786583065986633, -0.026841221377253532, 0.045332714915275574, -0.08430710434913635, 0.047327540814876556, 0.06760399788618088, -0.11452443152666092, -0.13476863503456116, -0.055132701992988586, -0.09432056546211243, 0.011720843613147736, 0.17093253135681152, -0.08602166920900345, -0.06228332966566086, 0.06895031780004501, -0.04303541034460068, -0.11472778022289276, 0.07226449251174927, -0.09889176487922668, -0.041116856038570404, 0.11293371766805649, -0.05874611809849739, -0.15312501788139343, -0.008785903453826904, -0.01730402186512947, -0.05369354039430618, -0.014541341923177242, -0.016575373709201813, 0.04343295842409134, 0.1719513237476349, -0.044837914407253265, -0.1275242269039154, 0.02641969546675682, 0.07370317727327347, -0.03423219174146652, 0.08507878333330154, -0.16357818245887756, -0.05903591960668564, -0.16437295079231262, 0.017947625368833542, -0.03405263274908066, -0.08911532908678055, -0.05963066592812538, -0.050326429307460785, 0.11837777495384216, 0.04674835875630379, -0.06519133597612381, -0.10271792113780975, -0.15894727408885956, -0.0005671512335538864, 0.08681624382734299, -0.11320093274116516, -0.008086294867098331, 0.024352066218852997, -0.013529935851693153, 0.10340215265750885, 0.2345600426197052, 0.03404312953352928, 0.08205430209636688, -0.15230579674243927, 0.10258948057889938, 0.11872279644012451, 0.06121760606765747, 0.007016608491539955, 0.12636329233646393, 0.07449105381965637, 0.04718243330717087, 0.1350877583026886, 0.006390706170350313, 0.02355262264609337, 0.0694795697927475, -0.009419362060725689, -0.04085979610681534, -0.07628950476646423, -0.04167266562581062, -0.01687455177307129, -0.019153686240315437, -0.023238979279994965, 0.046648867428302765, 0.08370180428028107, 0.09883639216423035, -0.0020256247371435165, -0.037812307476997375, -0.1533280909061432, -0.018701966851949692, -0.0030526898335665464, 0.08597606420516968, -0.09208635240793228, 0.0036089797504246235, 0.11265626549720764, -0.12263645976781845, 0.040998414158821106, -0.042380623519420624, -0.036055125296115875, -0.036700546741485596, 0.17200405895709991, -0.08163812756538391, 0.06462523341178894, 0.2752808928489685, -0.15026669204235077, 0.021011527627706528, 0.08436460793018341, 0.07773330807685852, 0.0538465678691864, 0.03230855613946915, 0.00848973635584116, -0.13773025572299957, 1.2804795145357522e-32, -0.13837260007858276, 0.09163357317447662, -0.08864390850067139, -0.11295589804649353, -0.00976656749844551, 0.041373711079359055, 0.13844703137874603, 0.12077222019433975, -0.06867024302482605, -0.05611862242221832, -0.2859937846660614, 0.05289410054683685, 0.07883748412132263, 0.1236223578453064, 0.03924001008272171, -0.0898343175649643, 0.07425540685653687, -0.01869926229119301, 0.07086202502250671, -0.11617026478052139, 0.05070137232542038, -0.013201173394918442, -0.0664544552564621, 0.12856821715831757, -0.11574076116085052, -0.010236624628305435, -0.09081565588712692, 0.054016731679439545, 0.046747028827667236, 0.03149475157260895, -0.08473225682973862, 0.1324971467256546, 0.07266701757907867, -0.09889284521341324, -0.07160443067550659, 0.08360899984836578, -0.046110302209854126, -0.08174510300159454, 0.12468227744102478, -0.024242334067821503, -0.017331691458821297, 0.25162482261657715, -0.10233627259731293, -0.11067435145378113, -0.10481829941272736, -0.0735454261302948, -0.07707556337118149, -0.01085636019706726, 0.08084207773208618, -0.13958725333213806, -0.035908617079257965, 0.07632473111152649, -0.005509030073881149, -0.09860020875930786, -0.07585907727479935, -0.01015147753059864, -0.19248118996620178, -0.06142402067780495, 0.12219065427780151, 0.1477133333683014, 0.05152910575270653, 0.01712939515709877, -0.03063477948307991, -0.009096089750528336, -0.16873571276664734, 0.23528268933296204, 0.1095682829618454, -0.07217439264059067, 0.005663776770234108, -0.03037446178495884, -0.005703262984752655, -0.03971809893846512, 0.09585990011692047, -0.06396849453449249, 0.1556546688079834, -0.021517913788557053, 0.11640995740890503, 0.011754324659705162, 0.028801770880818367, 0.04206563159823418, 0.01075226441025734, 0.027461858466267586, -0.005853248294442892, 0.14702847599983215, 0.08663474023342133, 0.011176088824868202, 0.052947454154491425, 0.01661556400358677, -0.16137093305587769, -0.0011075064539909363, 0.13814668357372284, -0.01898740977048874, -0.041504740715026855, 0.07943006604909897, -0.03937801718711853, -1.2997777522299956e-32, -0.09027229994535446, 0.11831147968769073, -0.04754259064793587, -0.07820816338062286, 0.010156848467886448, 0.04419197142124176, 0.02567530795931816, -0.03966841846704483, -0.04205302894115448, -0.020946769043803215, 0.09649498760700226, 0.08084280043840408, -0.021339043974876404, -0.03847547993063927, -0.11475751549005508, -0.0774695947766304, -0.13396990299224854, -0.014130973257124424, 0.16683951020240784, 0.023721111938357353, 0.08252571523189545, 0.3072885572910309, -0.10398132354021072, 0.0529666468501091, 0.03592325747013092, 0.035858891904354095, 0.015393114648759365, 0.06525541841983795, 0.025255795568227768, 0.03739536553621292, -0.1221727505326271, 0.003048123326152563, -0.2600858807563782, -0.08013993501663208, -0.03869500756263733, 0.06299255788326263, 0.0019233636558055878, -0.1395244598388672, -0.17517432570457458, -0.04960370436310768, 0.12654165923595428, -0.050672609359025955, -0.02943047136068344, 0.04484046250581741, 0.16599756479263306, -0.11994114518165588, -0.07277005165815353, 0.028218016028404236, 0.1064048558473587, -0.007705090567469597, -0.032756805419921875, 0.04969928413629532, -0.013924824073910713, 0.02413824200630188, -0.15736261010169983, 0.025700360536575317, 0.04795350879430771, -0.026604056358337402, -0.08640912175178528, -0.09323778748512268, -0.058191508054733276, 0.040144432336091995, -0.04561029374599457, -0.07928253710269928, 0.13689562678337097, 0.08668403327465057, 0.10513891279697418, 0.015958212316036224, 0.007906092330813408, -0.1463077962398529, 0.005572343710809946, 0.10337105393409729, -0.03688940405845642, -0.06272921711206436, -0.008758307434618473, 0.12876373529434204, 0.05657362937927246, -0.15381763875484467, -0.05080241337418556, -0.04520662873983383, -0.062453996390104294, 0.0496458075940609, 0.05096951872110367, 0.0804281234741211, -0.0793227106332779, -0.010527659207582474, 0.08316240459680557, -0.020399369299411774, -0.17072762548923492, 0.08162038028240204, -0.06456273794174194, -0.18974676728248596, -0.10695432126522064, 0.1647932529449463, 0.04188793897628784, -1.0120042759353964e-07, 0.10062335431575775, 0.05160723999142647, 0.03761719912290573, -0.015315682627260685, 0.05055234581232071, -0.04860281944274902, -0.061978720128536224, 0.081721231341362, 0.011621590703725815, 0.12237939238548279, 0.008354472927749157, 0.18102121353149414, -0.11137662827968597, -0.02019999921321869, -0.15894682705402374, 0.1475781798362732, -0.0925622284412384, 0.08228899538516998, -0.041513945907354355, -0.14850518107414246, -0.06386955827474594, 0.09700149297714233, 0.054929062724113464, -0.04645591229200363, 0.037352077662944794, -0.1012851744890213, 0.020862719044089317, 0.11982757598161697, -0.04103239253163338, -0.09048677235841751, -0.06440731883049011, 0.013787983916699886, 0.1958225816488266, -0.06424131989479065, 0.002620421350002289, -0.2457820326089859, -0.01078018918633461, 0.08737090229988098, 0.06829938292503357, -0.03498387336730957, -0.08946114033460617, -0.03285868093371391, 0.014583583921194077, 0.05050042271614075, 0.020912261679768562, -0.11975133419036865, -0.11240901052951813, -0.16008329391479492, 0.06538829952478409, -0.1317860186100006, 0.1435619294643402, 0.03324216231703758, 0.03561078757047653, -0.0925862193107605, -0.026640748605132103, -0.016263261437416077, -0.13538911938667297, -0.1130969375371933, -0.11266475915908813, 0.029835885390639305, 0.10622910410165787, -0.16680693626403809, 0.05211557447910309, 0.005365393124520779], "changes": {"1wk": 2.985326555105605}}, {"text": "LIVE The latest news and updates on Trump's tariffs Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 Axsome Therapeutics, Inc. Wed, Jan 22, 2025, 3:00 PM 5 min read In This Article: AXSM Axsome Therapeutics, Inc. NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the \u201cWebcasts & Presentations\u201d page of the \u201cInvestors\u201d section of the Company\u2019s website at www.axsome.com . A replay of the conference call will be available on the Company\u2019s website for approximately 30 days following the live event. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder and excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain\u2019s biggest problems so patients and their loved ones can flourish. Forward Looking Statements Certain matters discussed in this press release are \u201cforward-looking statements\u201d. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company\u2019s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of the Company\u2019s Sunosi\u00ae and Auvelity\u00ae products and the success of the Company\u2019s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company\u2019s ability to maintain and expand payer coverage; the success, timing and cost of the Company\u2019s ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund the Company\u2019s disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (\u201cNDA\u201d) for any of the Company\u2019s current product candidates, including statements regarding the ability of the ACCORD and ADVANCE clinical trials to support the filing of an NDA for Alzheimer\u2019s disease agitation; the Company\u2019s ability to fund additional clinical trials to continue the advancement of the Company\u2019s product candidates; the timing of and the Company\u2019s ability to obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, the Company\u2019s product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company\u2019s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to the Company\u2019s special protocol assessment for the MOMENTUM clinical trial; the Company\u2019s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company\u2019s research and development programs and collaborations; the success of the Company\u2019s license agreements; the acceptance by the market of the Company\u2019s products and product candidates, if approved; the Company\u2019s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company\u2019s commercial launch of its other product candidates, if approved, and the potential impact on the Company\u2019s anticipated cash runway; the Company\u2019s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company\u2019s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. Story Continues Investors: Mark Jacobson Chief Operating Officer (212) 332-3243 mjacobson@axsome.com Media: Darren Opland Director, Corporate Communications (929) 837-1065 dopland@axsome.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXSM", "date": "2025-01-22T15:00:00", "sentiment": {"score": 0.17199470568448305, "confidence": 0.18173348903656006, "probabilities": {"positive": 0.18173348903656006, "negative": 0.009738783352077007, "neutral": 0.8085277676582336}}, "embedding": [-0.14823146164417267, -0.06769992411136627, -0.0038328533992171288, 0.02988087385892868, 0.03863251954317093, -0.0676967203617096, 0.023785339668393135, 0.12122558057308197, 0.05851738527417183, 0.03355861455202103, -0.13909289240837097, 0.11523987352848053, 0.005369942635297775, 0.06386642903089523, -0.041523102670907974, 0.038935594260692596, 0.04805628955364227, -0.08002828806638718, -0.09887667000293732, 0.13568025827407837, 0.05771955847740173, 0.07271607220172882, 0.10500204563140869, 0.013110863044857979, -0.0415324829518795, 0.016056755557656288, -0.09003514051437378, -0.1035708338022232, -0.09618543088436127, -0.06629078090190887, 0.06330567598342896, 0.20643451809883118, -0.02990265190601349, -0.0350593738257885, 0.10483808815479279, 0.03789721429347992, -0.10358357429504395, 0.045339468866586685, -0.051919251680374146, -0.04002987593412399, 0.09023240208625793, -0.07021641731262207, -0.01710851863026619, 0.09668663889169693, -0.10850867629051208, -0.06815243512392044, -0.07436658442020416, -0.047708965837955475, 0.013911224901676178, 0.1383167803287506, -0.10329926013946533, -0.16363216936588287, 0.008750205859541893, 0.06263729184865952, 0.025886567309498787, 0.07047438621520996, -0.11108196526765823, -0.008833988569676876, -0.08877883106470108, 0.0384519100189209, 0.013014089316129684, -0.0013947556726634502, -0.02752269059419632, 0.021405445411801338, 0.11887427419424057, 0.14070379734039307, -0.04905623197555542, -0.03114013932645321, -0.1106162816286087, -0.04421767592430115, 0.04849168658256531, -0.12089528888463974, 0.02964247763156891, 0.055789776146411896, -0.006520890165120363, 0.05485612899065018, 0.16627386212348938, -0.015698136761784554, 0.14517652988433838, -0.0492929145693779, 0.04646722599864006, 0.05793508142232895, 0.08765213191509247, 0.03379480540752411, 0.08556711673736572, 0.062036313116550446, 0.06124686822295189, 0.08909819275140762, -0.03107364848256111, -0.009330370463430882, 0.011397936381399632, -0.09767409414052963, -0.011557497084140778, 0.009857360273599625, -0.07623869180679321, -0.025480829179286957, 0.0011448853183537722, -0.030473917722702026, -0.047583963721990585, 0.07236664742231369, 0.05559135228395462, 0.04967852681875229, -0.002560088410973549, -0.10249024629592896, -0.07206185162067413, 0.00014878809452056885, 0.05048967897891998, -0.04676596075296402, 0.011115698143839836, 0.08703449368476868, -0.13293680548667908, 0.025140590965747833, -0.01793140172958374, -0.019172223284840584, -0.009412996470928192, 0.12595996260643005, -0.055447474122047424, 0.06971336901187897, 0.2614215612411499, -0.09095053374767303, 0.02756178379058838, 0.09035094082355499, 0.03672381490468979, -0.1018923670053482, 0.04073074832558632, -0.015046040527522564, -0.168063223361969, 7.203045142123053e-33, -0.10377198457717896, -0.009812937118113041, -0.03692525997757912, 0.016105394810438156, 0.0009391410276293755, -0.03203295171260834, 0.06540092080831528, 0.03138142451643944, -0.07135740667581558, 0.01583835296332836, -0.20780013501644135, 0.02445772849023342, 0.09539814293384552, 0.1292358636856079, -0.07069935649633408, -0.1462770402431488, 0.03528561815619469, -0.020286310464143753, 0.026682663708925247, -0.06076793000102043, 0.06412631273269653, 0.03656979277729988, -0.049710050225257874, 0.12117834389209747, -0.03494329750537872, -0.0319896899163723, -0.07951905578374863, 0.05521852523088455, 0.11143652349710464, 0.03479701280593872, -0.13715991377830505, 0.14061442017555237, -0.017020247876644135, -0.08510492742061615, -0.02641213685274124, 0.06587031483650208, -0.02817803993821144, -0.08324852585792542, 0.000610084505751729, 0.002574312034994364, -0.06158818304538727, 0.1075650304555893, -0.16114479303359985, -0.051344260573387146, 0.03682525083422661, -0.05753832682967186, -0.09459555149078369, -0.010632943361997604, 0.0603327751159668, -0.07644126564264297, -0.04472209885716438, 0.019406458362936974, -0.014767888933420181, -0.1017221063375473, -0.13547708094120026, 0.010935353115200996, -0.18259863555431366, -0.18531440198421478, 0.06543940305709839, 0.024855446070432663, 0.13601651787757874, -0.0062125385738909245, -0.05434270575642586, -0.05305278301239014, -0.10205452144145966, 0.11442840844392776, 0.02625390514731407, -0.14205387234687805, -0.04067019000649452, 0.01100890338420868, -0.005902428179979324, -0.021440573036670685, 0.1734701544046402, -0.00681653805077076, 0.1065816879272461, -0.0106379808858037, 0.008749432861804962, 0.048314228653907776, -0.002434195950627327, 0.023427773267030716, 0.07012173533439636, -0.034660954028367996, -0.06456651538610458, 0.13722357153892517, 0.10131951421499252, -0.010450353845953941, 0.0215553417801857, 0.05603940039873123, -0.14933687448501587, -0.03221113234758377, 0.02384086512029171, -0.06485484540462494, 0.0406210720539093, 0.08560770750045776, -0.07222308218479156, -8.914852913036255e-33, -0.04376474767923355, -0.013137482106685638, -0.02445259317755699, -0.1000879555940628, 0.033558595925569534, 0.029645495116710663, 0.026347439736127853, -0.004915889352560043, 0.06377076357603073, 0.009021449834108353, 0.04374336823821068, 0.040103018283843994, 0.04708985984325409, -0.0546293780207634, -0.06738724559545517, -0.058049850165843964, -0.11196955293416977, -0.08061009645462036, 0.02783110924065113, 0.09804907441139221, 0.07509671151638031, 0.19974225759506226, -0.152617946267128, 0.025628725066781044, 0.037800054997205734, 0.05151303857564926, 0.09645940363407135, 0.10809111595153809, 0.06267663091421127, -0.023953605443239212, -0.20401757955551147, -0.005463676527142525, -0.26258325576782227, -0.007078022696077824, -0.031985096633434296, 0.07415798306465149, 0.06621477007865906, -0.17264121770858765, -0.18468144536018372, -0.17548495531082153, 0.14194205403327942, 0.008556604385375977, -0.012701604515314102, 0.11831354349851608, 0.1600673794746399, -0.02820689044892788, -0.07626110315322876, 0.014774009585380554, 0.05675991252064705, -0.04852904751896858, -0.02677101641893387, 0.07455389201641083, -0.003659890964627266, -0.00487001845613122, -0.05175080522894859, -0.02760336548089981, 0.0206823218613863, -0.07768978923559189, -0.04914955422282219, 0.012107676826417446, -0.054066725075244904, 0.09790901839733124, -0.02664000540971756, -0.017553063109517097, 0.1670164167881012, 0.0778009369969368, 0.01445043832063675, -0.016493644565343857, 0.08034352958202362, -0.04721157252788544, 0.08462733775377274, 0.03772342950105667, -0.043538134545087814, -0.05675675719976425, 0.032309144735336304, 0.0352005772292614, -0.045627325773239136, -0.14076754450798035, -0.08314643800258636, 0.0415184460580349, 0.08873884379863739, 0.0018641222268342972, 0.04730109125375748, 0.11497699469327927, -0.04026767611503601, 0.004824042320251465, 0.09516197443008423, 0.0673198476433754, -0.07219363749027252, -0.018050115555524826, -0.0806950181722641, -0.16155436635017395, -0.16987156867980957, 0.1871829628944397, 0.018900178372859955, -1.0108608705650113e-07, 0.09247873723506927, -0.018192626535892487, 0.01680910214781761, -0.08586657047271729, 0.027586882933974266, -0.009042423218488693, -0.0375942587852478, -0.018422957509756088, 0.0018658936023712158, 0.11642567068338394, 0.06487832963466644, 0.13516008853912354, -0.08990490436553955, 0.04552806541323662, -0.0745522752404213, 0.046474386006593704, -0.08808709681034088, 0.05839512497186661, -0.033713728189468384, -0.12281442433595657, -0.05837436765432358, 0.010979901999235153, 0.02583160251379013, -0.029521629214286804, 0.0881292000412941, -0.04538767784833908, -0.0034802518784999847, 0.11631964147090912, -0.08189098536968231, -0.10493499040603638, -0.12346598505973816, 0.03508925065398216, 0.09990783035755157, -0.0662032812833786, -0.04478713870048523, -0.15906885266304016, 0.03657514974474907, 0.030418770387768745, 0.11715461313724518, 0.0435861274600029, -0.06294427812099457, 0.039610229432582855, 0.009333739057183266, 0.049022041261196136, 0.03696545958518982, -0.12814609706401825, -0.019090814515948296, -0.1019056886434555, 0.060017410665750504, -0.0628277137875557, 0.02874116785824299, -0.023307383060455322, 0.0360192246735096, -0.037680502980947495, -0.03188097104430199, 0.06478604674339294, -0.12178537249565125, -0.06382600963115692, -0.05011095851659775, -0.01569552905857563, 0.14226746559143066, -0.08785070478916168, 0.03273790702223778, 0.04495938494801521], "changes": {"1wk": 0.18578512529865385}}, {"text": "LIVE The latest news and updates on Trump's tariffs Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last? Zacks Equity Research Tue, Jan 14, 2025, 5:05 PM 2 min read In This Article: MIRM Axsome Therapeutics (AXSM) shares ended the last trading session 11.5% higher at $89.27. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.2% loss over the past four weeks. The stock rallied after the company announced robust preliminary net product revenues for its marketed drugs, Auvelity and Sunosi, for the fourth quarter and full year 2024. Auvelity sales in the fourth quarter of 2024 are expected to be around $92.6 million, bringing the full-year number to $291.4 million. Sunosi net product revenues are expected to be around $25.7 million and $93.8 million for the fourth quarter and full year of 2024, respectively. This biopharmaceutical company is expected to post quarterly loss of $0.97 per share in its upcoming report, which represents a year-over-year change of -32.9%. Revenues are expected to be $115.68 million, up 61.7% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For Axsome, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on AXSM going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Axsome belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Mirum Pharmaceuticals, Inc. (MIRM), closed the last trading session 6.5% higher at $44. Over the past month, MIRM has returned -2.6%. Mirum Pharmaceuticals' consensus EPS estimate for the upcoming report has changed +24.7% over the past month to -$0.29. Compared to the company's year-ago EPS, this represents a change of +56.1%. Mirum Pharmaceuticals currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report Mirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXSM", "date": "2025-01-14T17:05:00", "sentiment": {"score": 0.5129473060369492, "confidence": 0.6986455321311951, "probabilities": {"positive": 0.6986455321311951, "negative": 0.1856982260942459, "neutral": 0.11565626412630081}}, "embedding": [-0.04565411061048508, -0.092115119099617, -0.03193330019712448, -0.0013916203752160072, 0.027628056704998016, -0.01386336050927639, 0.02393963374197483, 0.18784114718437195, 0.054928094148635864, 0.12456002086400986, -0.06872175633907318, 0.1508743166923523, -0.04027165472507477, 0.028368739411234856, -0.05969075858592987, 0.050289884209632874, 0.021050404757261276, -0.025323159992694855, -0.18074515461921692, 0.11088518053293228, -0.023035582154989243, -0.05132598802447319, 0.08474278450012207, -0.02957993373274803, 0.09084977209568024, 0.09302692115306854, -0.06024087965488434, -0.034385692328214645, -0.12721143662929535, -0.14985430240631104, -0.06238224357366562, 0.13043269515037537, 0.046725742518901825, -0.042052678763866425, 0.03966924548149109, -0.02846544235944748, 0.0013589505106210709, -0.007396770641207695, 0.07570302486419678, -0.04240434244275093, 0.06509801000356674, -0.009925819002091885, -0.10690723359584808, -0.015522276982665062, -0.10115256160497665, -0.06762761622667313, 0.003366011194884777, -0.02136095240712166, 0.13682842254638672, 0.16864220798015594, -0.1381763517856598, -0.07056444883346558, -0.0010563584510236979, 0.07303189486265182, -0.05795634910464287, 0.06506318598985672, -0.05714893713593483, -0.05253595858812332, -0.02951042726635933, 0.05094742029905319, 0.0544230192899704, -0.056298770010471344, -0.02255261316895485, -0.006395044736564159, 0.16362275183200836, -0.04454535245895386, -0.03642519935965538, -0.04656515270471573, -0.08762813359498978, 0.047779619693756104, 0.1147175058722496, -0.10411721467971802, -0.11684221029281616, -0.0026449384167790413, -0.12386015057563782, 0.10204422473907471, 0.19247666001319885, 0.014031007885932922, 0.07362817972898483, -0.06023544818162918, 0.037341535091400146, 0.08701547235250473, -0.002385009080171585, -0.02707955241203308, 0.05672615021467209, 0.03125850111246109, 0.10184159874916077, 0.13551847636699677, 0.07196982204914093, 0.027986351400613785, 0.008493976667523384, 0.01211339421570301, -0.021958867087960243, -0.027908191084861755, 0.007045714184641838, 0.030638426542282104, -0.013061361387372017, 0.002457750029861927, 0.0017189751379191875, 0.09774218499660492, 0.1288008689880371, 0.10973680764436722, -0.07166728377342224, -0.13199473917484283, -0.018956273794174194, -0.0856311246752739, 0.042493097484111786, -0.07327727973461151, 0.01573367603123188, 0.15179871022701263, -0.0626954585313797, 0.0948028415441513, -0.1205100417137146, -0.005774898454546928, -0.06436298787593842, 0.09473094344139099, 0.02777530997991562, -0.00044609163887798786, 0.07330731302499771, -0.03751220554113388, 0.04828602820634842, 0.083595871925354, 0.05513433367013931, 0.03869551047682762, 0.028313124552369118, 0.04504070430994034, -0.1492810696363449, 9.242444086827226e-33, -0.034520652145147324, 0.06859944760799408, -0.06282566487789154, -0.04191477969288826, -0.03817048668861389, 0.07412603497505188, 0.09837737679481506, -0.008723864331841469, -0.09819482266902924, -0.05667515844106674, -0.27891427278518677, 0.09815144538879395, -0.021348563954234123, -0.016346514225006104, 0.014219923876225948, -0.15851911902427673, 0.054204970598220825, -0.037797167897224426, 0.04669990390539169, -0.09949144721031189, 0.0013103135861456394, 0.010272704064846039, -0.12059897184371948, 0.07711008191108704, -0.0650697648525238, 0.007300945930182934, -0.00485154427587986, 0.08067965507507324, -0.02134058065712452, 0.02234741300344467, -0.021796073764562607, 0.06279496848583221, -0.013624357059597969, -0.07842010259628296, -0.01592208817601204, 0.006069697439670563, -0.06801038980484009, -0.017921648919582367, 0.15520355105400085, -0.008094565011560917, -0.0933527797460556, 0.19393455982208252, -0.08836983144283295, -0.1072017103433609, -0.08519459515810013, -0.036322034895420074, -0.09574215859174728, -0.018308550119400024, 0.040759630501270294, -0.07092853635549545, -0.10274869948625565, 0.03728290647268295, 0.036914702504873276, -0.02141861617565155, -0.08159475028514862, -0.031555868685245514, -0.1263146698474884, -0.13421575725078583, 0.020814664661884308, 0.11615853011608124, 0.05935029685497284, 0.10811387002468109, 0.03610328584909439, 0.03842441365122795, -0.1781516671180725, 0.20899689197540283, -0.034664519131183624, 0.02206292375922203, -0.07035033404827118, 0.1487293541431427, 0.036894649267196655, -0.03224390000104904, 0.10048443078994751, -0.10146787762641907, 0.15642914175987244, -0.06513433903455734, 0.0057305991649627686, -0.004492708016186953, 0.03896714001893997, 0.0680646225810051, 0.09870510548353195, -0.004132718313485384, 0.04622993618249893, 0.05702310800552368, -0.08138253539800644, 0.0004139789380133152, 0.010033667087554932, -0.003983600065112114, -0.07468334585428238, 0.02970324084162712, 0.09961903095245361, -0.09858660399913788, -0.05701744183897972, 0.07985535264015198, -0.062011078000068665, -8.976855831938315e-33, -0.0777561366558075, 0.07282619178295135, -0.0006661722436547279, -0.01741824485361576, -0.06459818035364151, -0.010548701509833336, 0.07171740382909775, 0.08786201477050781, -0.10307541489601135, 0.0034374110400676727, 0.09927847236394882, 0.044742655009031296, -0.021445685997605324, 0.0325942300260067, -0.06409014761447906, -0.015515496954321861, 0.04975852370262146, -0.04768242686986923, 0.12094461172819138, -0.0763452798128128, -0.0233113095164299, 0.23951542377471924, -0.13896432518959045, 0.10664160549640656, -0.05372653901576996, 0.028634436428546906, -0.0054049137979745865, 0.07036184519529343, 0.024580705910921097, -0.07443305850028992, -0.02335251495242119, -0.0012197266332805157, -0.18392612040042877, 0.09024311602115631, 0.021758049726486206, 0.05405715852975845, -0.0382780060172081, -0.12221025675535202, -0.06517407298088074, -0.04392353072762489, 0.15735560655593872, -0.006682807579636574, 0.013727542012929916, 0.05802485719323158, 0.13053323328495026, -0.06304766237735748, -0.08052058517932892, 0.04086529463529587, 0.19075825810432434, 0.06789708137512207, -0.05621705204248428, 0.029414568096399307, -0.027143051847815514, 0.08384420722723007, -0.0784936249256134, 0.06899090111255646, 0.022765476256608963, 0.026609163731336594, -0.12844029068946838, 0.003559791250154376, -0.010795025154948235, 0.09020832926034927, 0.005325608421117067, -0.038818880915641785, 0.025574835017323494, 0.0860903263092041, 0.020764946937561035, -0.006109403446316719, 0.05321932211518288, -0.059506744146347046, 0.08995461463928223, -0.010535890236496925, 0.08602379262447357, -0.10038742423057556, 0.02101818285882473, 0.11665256321430206, 0.005388281308114529, -0.13552799820899963, -0.09461294114589691, -0.00013018399477005005, 0.023707102984189987, 0.045419707894325256, 0.025869175791740417, 0.038789715617895126, -0.11122579127550125, 0.1050855964422226, 0.04544148966670036, 0.03602023795247078, -0.18938030302524567, 0.02651318535208702, -0.05098675563931465, -0.20096972584724426, -0.13696366548538208, 0.07806704938411713, 0.05350704863667488, -9.982602477975888e-08, 0.08054713904857635, -0.06112515181303024, 0.06226044148206711, -0.006766395643353462, 0.07943132519721985, 0.048019807785749435, -0.007732408121228218, -0.018223049119114876, 0.0839829295873642, 0.18696048855781555, 0.05657384544610977, 0.10098345577716827, -0.24288161098957062, 0.03479434549808502, -0.18809302151203156, 0.07195092737674713, -0.0961756557226181, 0.032133251428604126, 0.013908467255532742, -0.16039890050888062, -0.08357330411672592, 0.09773306548595428, 0.0875517800450325, -0.023721735924482346, 0.008082196116447449, -0.01882779225707054, -0.04280630499124527, 0.07399715483188629, 0.006297549232840538, -0.015173195861279964, -0.002663958817720413, -0.009409522637724876, 0.11020401120185852, 0.002043777843937278, -0.0496286042034626, -0.09451353549957275, 0.00726746954023838, 0.04752042889595032, 0.07018718123435974, 0.05149419605731964, -0.054093897342681885, -0.012124134227633476, -1.2535136193037033e-05, 0.052262283861637115, -0.013139726594090462, -0.08653202652931213, -0.13360115885734558, -0.11798181384801865, 0.07466679066419601, -0.18918180465698242, 0.13951076567173004, 0.03024083562195301, 0.0016520936042070389, -0.007837100885808468, -0.03486485034227371, 0.007328798994421959, -0.21376678347587585, -0.05979539453983307, -0.15305954217910767, 0.005644636228680611, 0.07846516370773315, -0.27404990792274475, -0.006081241182982922, 0.08421853184700012], "changes": {"1wk": 8.67021184015318}}, {"text": "LIVE The latest news and updates on Trump's tariffs Can Analysts Pick Stocks? I Doubt It John Dorfman Mon, Jan 13, 2025, 7:22 PM 4 min read In This Article: SLB January 13, 2025 (Maple Hill Syndicate) Can professional analysts pick stocks? Don't laugh. Analysts perform many valuable functions. They ask probing questions to management, estimate earnings, and provide a wealth of information on companies and industries. However, a study I've been conducting for a quarter of a century suggests they are no better at picking stocks than your Aunt Louise. Warning! GuruFocus has detected 3 Warning Sign with SLB. Each January, I make note of the four stocks analysts most adore, and the four they most despise. When the year is over, I compare how those two groups of stocks have done. The results are not favorable to Wall Street. On average, over 26 years, the analysts' darlings have returned 7.25%. The stocks they hate have averaged 6.89%. Neither group beats the Standard & Poor's 500 Total ReturnIndex, which rolled in at 12.57% per year. My study covers every year from 1998 through 2024, except for 2008 when I was temporarily retired as a columnist. Figures are total returns, including dividends and capital gains or losses. Latest Scores A year ago, the most popular stock among analysts was Schlumberger Ltd. ( NYSE:SLB ), which garnered 20 buy ratings with nary a hold or sell in sight. What did Schlumberger do for the year? It fell 24.4%. Privia Health Group Inc. ( NASDAQ:PRVA ), which was fourth on analysts' most-loved list, also fell. It lost 15.1% of its value. Better was S&P Global Inc. ( NYSE:SPGI ), which returned 13.9%. And the analysts had one big winner: Targa Resources Corp. ( NYSE:TRGP ) more than doubled, returning 110.1%. That pulled the analysts' average up to 21.1% for2024. What about the stocks that analysts despised? They all had modest gains. Avista Corp. ( NYSE:AVA ) was up 7.8%, Southern Copper Corp. ( NYSE:SCCO ) up 8.3%, and Chenierre Energy Partners ( NYSE:CQP ) up 14.3%. The best performer for the hated brigade was Moelis & Co. ( NYSE:MC ), which returned 37.3%. Collectively, the stocks that Wall Street wouldn't touchachieved a 16.9% return, a little more than four percentage points below the analysts' favorites. Running Tally In 26 outings, the analysts' most-adored stocks have beaten their most-despised names 14 times. The despised brigade have won 11 times, and there was one tie. Against the S&P 500, neither group distinguished itself. The analysts' favorite have beaten the index only seven times out of 26, while the despised issues have beaten it 10 times. Data for the study come from Zacks Investment Research, Bloomberg and Ned Davis Research. Story Continues Most Adored The two stocks analysts most favor as 2025 begins are both airline stocks. United Airlines Holdings Inc. ( NASDAQ:UAL ) get 22 buy ratings, with no sells or holds. The analytical corps is almost equally bullish on Delta AirLines Inc. ( NYSE:DAL ) with 21 unanimous recommendations. It's easy to see why the analysts have warmed up to airlines. Traffic has picked up for both business and leisure travel, and jet fuel is not too expensive these days. But let's remember that Warren Buffett ( Trades , Portfolio ) once said it would have been good for investors if someone had shot Orville and Wilbur Wright. Third on the adored list is Arcelix Inc. ( NASDAQ:ACLX ) with 19 recommendations and no dissents. Arcelix, based in Redwood, California, is a biotech company that says it is reimagining cell therapy through thedevelopment of immunotherapies for patients with cancer and other incurable diseases. A worthy goal, to be sure. But Arcelix had revenue of just under $156 million in the past four quarters, while the market values the stock at $3.47 billion. Several company insiders have sold some of their stock in thepast few months. Rounding out the adored group is Axsome Therapeutics ( NASDAQ:AXSM ) unanimously endorsed by 18 analysts. The company, based in New York City, is developing therapies for diseases of the central nervous system. Most Hated On the list of stocks that analysts can't stand, ZIM Integrated Shipping Services Ltd. (ZIM) ranks first, with five out of seven analysts suggesting that people dump the stock. The stock sells for about $19, down from about $77 four years ago. ZIM has lost money in six of the past ten years. Ginko Bioworks Holdings Inc. ( NYSE:DNA ), a Boston-based bioengineering company, is ranked sell by four of the six analysts who cover it. Losses are narrowing, but analysts don't expect a profit before 2027. CNX Resources Corp. ( NYSE:CNX ) gets eight sell ratings from the 13 analysts who follow it. Based in Canonsburg, Pennsylvania, it produces and transports natural gas in the Appalachian Basin. Finally, AMC Networks Inc. ( NASDAQ:AMCX ) is considered a sell by three of the five analysts who venture an opinion. I have a hunch the analysts darlings can beat their pariahs in 2025. But it's hard to be sure. And that is precisely the point. John Dorfman is chairman of Dorfman Value Investments LLC in Boston, Massachusetts, and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at jdorfman@dorfmanvalue.com. This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AXSM", "date": "2025-01-13T19:22:04", "sentiment": {"score": -0.699682280421257, "confidence": 0.7769638299942017, "probabilities": {"positive": 0.07728154957294464, "negative": 0.7769638299942017, "neutral": 0.1457545906305313}}, "embedding": [-0.03417850658297539, -0.14012598991394043, -0.09116894006729126, 0.14597481489181519, 0.0031518861651420593, 0.1162877231836319, 0.018127411603927612, 0.1029016524553299, 0.03876201808452606, -0.024251356720924377, -0.055975064635276794, 0.17862945795059204, -0.016638245433568954, -0.04289428889751434, -0.10477477312088013, 0.06856542825698853, 0.04236913472414017, -0.004638012498617172, -0.1254676729440689, 0.07117189466953278, -0.11916206777095795, -0.12665113806724548, -0.03141698241233826, -0.05450737476348877, 0.10609988868236542, -0.001545826904475689, -0.12100517749786377, -0.029569018632173538, -0.19132599234580994, -0.05820862203836441, -0.047391217201948166, 0.041443947702646255, 0.06683589518070221, -0.01716827228665352, -0.12432309985160828, 0.003612775355577469, -0.004149033688008785, 0.07007530331611633, 0.18488579988479614, -0.03428599238395691, 0.07533316314220428, 0.07283467799425125, -0.06406833976507187, 0.019264517351984978, -0.05920572578907013, -0.1511877179145813, 0.03748054429888725, 0.010810492560267448, -0.00546474102884531, 0.03488188236951828, -0.20343708992004395, 0.004572646226733923, 0.09133841842412949, -0.045240022242069244, -0.06116609647870064, 0.06068389117717743, -0.08093040436506271, -0.06262800097465515, 0.10460454225540161, 0.019392481073737144, -0.0908263772726059, -0.027569252997636795, 0.03596785292029381, -0.003351341001689434, 0.11582481861114502, -0.01564769633114338, -0.06860750913619995, 0.022839661687612534, -0.11965582519769669, 0.07341048866510391, 0.060698650777339935, -0.04434133321046829, -0.08543495088815689, 0.03287731111049652, -0.04405371844768524, 0.10014736652374268, 0.06815236806869507, 0.057050831615924835, 0.12741374969482422, -0.05274590104818344, 0.005459522362798452, -0.01978934369981289, -0.04972813278436661, -0.03017139807343483, -0.06374587118625641, -0.07248237729072571, 0.0636541098356247, 0.009204388596117496, 0.11078038811683655, -0.007131689228117466, 0.11713222414255142, 0.03337537869811058, 0.020824912935495377, -0.04756522923707962, 0.15883523225784302, -0.006735088303685188, -0.08129598200321198, -0.036563023924827576, -0.060631658881902695, 0.07971993088722229, 0.10436196625232697, 0.0429496169090271, -0.01951524056494236, -0.10918086767196655, -0.0946015864610672, -0.1882830560207367, 0.023208416998386383, -0.0016037654131650925, -0.06432928144931793, 0.08597054332494736, -0.0689065083861351, 0.13824303448200226, -0.0553467757999897, -0.056964997202157974, -0.021442268043756485, -0.04340533912181854, -0.04193183779716492, 0.00971982628107071, 0.07489216327667236, 0.02286688983440399, 0.08156557381153107, 0.22759218513965607, 0.09281189739704132, 0.10818596184253693, 0.08547502756118774, 0.06844890117645264, -0.17618414759635925, 9.419233294403113e-33, -0.02806204743683338, 0.020913394168019295, -0.01902112364768982, 0.018028361722826958, -0.13643962144851685, 0.030729707330465317, 0.012937871739268303, -0.06712834537029266, -0.04777764528989792, -0.027247728779911995, -0.09757760167121887, 0.22540347278118134, 0.01068211905658245, -0.05951569601893425, 0.043906424194574356, -0.0540710911154747, 0.004399079829454422, -0.0301952064037323, -0.015283879823982716, -0.06081400066614151, 0.04523903876543045, 0.09361741691827774, 0.06151064485311508, -0.022420672699809074, -0.07057254761457443, -0.12388388812541962, -0.027410954236984253, -0.04967112839221954, -0.08838264644145966, 0.014717604964971542, 0.09517492353916168, -0.0030547650530934334, -0.04981058090925217, -0.023198895156383514, 0.04109103977680206, -0.06373549997806549, -0.1078156977891922, 0.033904533833265305, 0.03468414768576622, 0.03750862926244736, -0.06395308673381805, 0.10307075083255768, -0.002648527268320322, 0.02151070162653923, 0.05356187745928764, 0.10045108944177628, -0.07261719554662704, 0.024653960019350052, 0.034750476479530334, -0.02551686018705368, -0.0888439267873764, -0.0013818300794810057, 0.03939903900027275, 0.030732668936252594, -0.07097584009170532, 0.10570675134658813, 0.013190805912017822, -0.07636003941297531, 0.10241109132766724, 0.01600109227001667, -0.028573699295520782, 0.2666001319885254, -0.03687054663896561, -0.1343204379081726, -0.1549985706806183, 0.19211998581886292, -0.07611273229122162, 0.17159977555274963, -0.16526545584201813, 0.1142973080277443, 0.1052025705575943, -0.06343546509742737, 0.1516447216272354, -0.05704650655388832, 0.065339595079422, -0.039090123027563095, -0.06920431554317474, 0.052254028618335724, 0.02389911189675331, -0.11496352404356003, 0.11260658502578735, -0.019610993564128876, 0.13158749043941498, -0.0862249955534935, -0.02054557576775551, -0.11495029926300049, 0.047680605202913284, -0.026058966293931007, 0.0737219974398613, 0.033642347902059555, -0.04275017976760864, -0.01001691073179245, -0.05072391778230667, 0.09129136800765991, -0.08306567370891571, -8.935272719277977e-33, -0.12025627493858337, -0.07473943382501602, 0.09185947477817535, 0.0902266800403595, -0.07575676590204239, -0.05506860092282295, 0.07484623789787292, -0.06650558859109879, -0.03418413922190666, -0.09550448507070541, 0.061216168105602264, -0.0033176536671817303, -0.05002812296152115, 0.08649595081806183, 0.03737430274486542, 0.028814861550927162, 0.048265207558870316, -0.12034975737333298, -0.11300190538167953, -0.11157198250293732, 0.0494542121887207, 0.15590891242027283, -0.14454016089439392, 0.18072620034217834, -0.02870604395866394, 0.056224189698696136, 0.14502865076065063, 0.03297736495733261, 0.04135395586490631, -0.054584894329309464, -0.03796934336423874, 0.04070432111620903, -0.10126277804374695, 0.11007900536060333, 0.012384145520627499, -0.027139505371451378, -0.08584558963775635, -0.0817764550447464, -0.10041892528533936, -0.10251744091510773, 0.08330797404050827, 0.021645324304699898, 0.028803424909710884, 0.04235376790165901, 0.10081250965595245, 0.06442350894212723, -0.028699424117803574, -0.02268892154097557, 0.061203137040138245, 0.05078939348459244, -0.09297579526901245, 0.0562579408288002, -0.02358439937233925, 0.11779497563838959, -0.12027181684970856, -0.0007674852386116982, 0.050891079008579254, -0.004623276647180319, -0.05506657809019089, 0.013631697744131088, -0.016755716875195503, 0.10918793082237244, 0.032452505081892014, -0.047076016664505005, 0.018984971567988396, -0.07618708163499832, -0.03631110116839409, -0.07148703932762146, -0.0156461913138628, -0.10021881759166718, -0.020760608837008476, -0.05141919478774071, 0.02112121880054474, -0.2008066624403, 0.01920519769191742, 0.31168848276138306, -0.10816238075494766, 0.02528347261250019, -0.06996673345565796, 0.1361020803451538, 0.06578026711940765, 0.09896677732467651, 0.08865942060947418, 0.0016259532421827316, 0.04940885305404663, 0.17665356397628784, 0.01846775971353054, -0.07068081200122833, -0.0569622777402401, -0.08477215468883514, -0.0033703576773405075, -0.25258201360702515, -0.02778480388224125, 0.018089309334754944, 0.07696409523487091, -9.993761551641e-08, -0.04920554161071777, 0.01788219064474106, 0.0569629892706871, -0.01661125011742115, 0.07021898776292801, -0.11585146188735962, -0.002161692827939987, -0.021027659997344017, -0.007430876139551401, 0.15354782342910767, 0.08799732476472855, -0.0037379309069365263, -0.2392670065164566, 0.022496474906802177, -0.05022021383047104, -0.0726623684167862, -0.04564408212900162, 0.01873636618256569, 0.020808173343539238, -0.11773261427879333, 0.11752483993768692, 0.014099961146712303, 0.06493330001831055, 0.051102448254823685, 0.07840152084827423, -0.03491895645856857, -0.05589328333735466, -0.036638904362916946, 0.026662880554795265, 0.040567509829998016, 0.00048496853560209274, -0.07966157048940659, 0.01980092190206051, -0.07784244418144226, 0.07612013816833496, 0.09448599815368652, 0.10733616352081299, 0.020096972584724426, 0.16298846900463104, 0.1581682711839676, -0.05806322395801544, -0.07135401666164398, 0.08875162154436111, -0.05776900798082352, -0.05995425581932068, -0.032388269901275635, -0.13842688500881195, 0.013592739589512348, 0.21662133932113647, -0.10046763718128204, 0.0825805738568306, -0.08158281445503235, -0.047328684478998184, 0.07725675404071808, 0.0818093866109848, -0.032763395458459854, -0.12371546030044556, -0.04519430547952652, -0.20556031167507172, -0.005567324813455343, 0.08615095913410187, -0.1909467875957489, -0.030756665393710136, 0.1587199866771698], "changes": {"1wk": 2.985326555105605}}]